A bacterial membrane sculpting protein with BAR domain-like activity

  1. Daniel A Phillips  Is a corresponding author
  2. Lori A Zacharoff  Is a corresponding author
  3. Cheri M Hampton
  4. Grace W Chong
  5. Anthony P Malanoski
  6. Lauren Ann Metskas
  7. Shuai Xu
  8. Lina J Bird
  9. Brian J Eddie
  10. Aleksandr E Miklos
  11. Grant J Jensen
  12. Lawrence F Drummy
  13. Mohamed Y El-Naggar
  14. Sarah M Glaven
  1. Oak Ridge Institute for Science and Education / US Army DEVCOM Chemical Biological Center, United States
  2. University of Southern California, United States
  3. Wright-Patterson Air Force Base, United States
  4. US Naval Research Laboratory, United States
  5. California Institute of Technology, United States
  6. US Army DEVCOM Chemical Biological Center, United States

Abstract

Bin/Amphiphysin/RVS (BAR) domain proteins belong to a superfamily of coiled-coil proteins influencing membrane curvature in eukaryotes and are associated with vesicle biogenesis, vesicle-mediated protein trafficking, and intracellular signaling. Here we report a bacterial protein with BAR domain-like activity, BdpA, from Shewanella oneidensis MR-1, known to produce redox-active membrane vesicles and micrometer-scale outer membrane extensions (OMEs). BdpA is required for uniform size distribution of membrane vesicles and influences scaffolding of OMEs into a consistent diameter and curvature. Cryogenic transmission electron microscopy reveals a strain lacking BdpA produces lobed, disordered OMEs rather than membrane tubules or narrow chains produced by the wild type strain. Overexpression of BdpA promotes OME formation during planktonic growth of S. oneidensis where they are not typically observed. Heterologous expression results in OME production in Marinobacter atlanticus and Escherichia coli. Based on the ability of BdpA to alter membrane architecture in vivo, we propose that BdpA and its homologs comprise a newly identified class of bacterial BAR domain-like proteins.

Data availability

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE [1] partner repository with the dataset identifier PXD020577.

The following data sets were generated

Article and author information

Author details

  1. Daniel A Phillips

    Oak Ridge Institute for Science and Education / US Army DEVCOM Chemical Biological Center, Aberdeen Proving Grounds, United States
    For correspondence
    daniel.a.phillips62.ctr@army.mil
    Competing interests
    Daniel A Phillips, DP and SG hold the patent US10793865B2 on Transferrable mechanism of generating inducible.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2759-5246
  2. Lori A Zacharoff

    Department of Physics and Astronomy, University of Southern California, Los Angeles, United States
    For correspondence
    zacharof@usc.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8657-0968
  3. Cheri M Hampton

    Materials and Manufacturing Directorate, Wright-Patterson Air Force Base, Dayton, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0069-8712
  4. Grace W Chong

    Department of Biological Sciences, University of Southern California, Los Angeles, United States
    Competing interests
    No competing interests declared.
  5. Anthony P Malanoski

    Center for Bio/Molecular Science and Engineering, US Naval Research Laboratory, Washington, United States
    Competing interests
    No competing interests declared.
  6. Lauren Ann Metskas

    Biological Sciences, Chemistry, California Institute of Technology, Pasadena, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8073-6960
  7. Shuai Xu

    Department of Physics and Astronomy, University of Southern California, Los Angeles, United States
    Competing interests
    No competing interests declared.
  8. Lina J Bird

    Center for Bio/Molecular Science and Engineering, US Naval Research Laboratory, Washington, United States
    Competing interests
    No competing interests declared.
  9. Brian J Eddie

    Center for Bio/Molecular Science and Engineering, US Naval Research Laboratory, Washington, United States
    Competing interests
    No competing interests declared.
  10. Aleksandr E Miklos

    BioSciences Division, BioChemistry Branch, US Army DEVCOM Chemical Biological Center, Aberdeen Proving Ground, United States
    Competing interests
    No competing interests declared.
  11. Grant J Jensen

    Biology and Bioengineering, California Institute of Technology, Pasadena, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1556-4864
  12. Lawrence F Drummy

    Materials and Manufacturing Directorate, Wright-Patterson Air Force Base, Dayton, United States
    Competing interests
    No competing interests declared.
  13. Mohamed Y El-Naggar

    Department of Physics and Astronomy, Biological Sciences, and Chemistry, University of Southern California, Los Angeles, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5599-6309
  14. Sarah M Glaven

    Center for Bio/Molecular Science and Engineering, US Naval Research Laboratory, Washington, United States
    Competing interests
    Sarah M Glaven, DP and SG hold the patent US10793865B2 on Transferrable mechanism of generating inducible.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0857-3391

Funding

U.S. Department of Defense

  • Sarah M Glaven

Office of Naval Research (N00014-18-1-2632)

  • Mohamed Y El-Naggar

National Science Foundation (DEB-1542527)

  • Mohamed Y El-Naggar

U.S. Department of Energy (DE-FG02-13ER16415)

  • Mohamed Y El-Naggar

National Institute of General Medical Sciences (GM122588)

  • Grant J Jensen

U.S. Army Combat Capabilities Development Command (PE 0601102A Project VR9)

  • Aleksandr E Miklos

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 2,362
    views
  • 347
    downloads
  • 5
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Daniel A Phillips
  2. Lori A Zacharoff
  3. Cheri M Hampton
  4. Grace W Chong
  5. Anthony P Malanoski
  6. Lauren Ann Metskas
  7. Shuai Xu
  8. Lina J Bird
  9. Brian J Eddie
  10. Aleksandr E Miklos
  11. Grant J Jensen
  12. Lawrence F Drummy
  13. Mohamed Y El-Naggar
  14. Sarah M Glaven
(2021)
A bacterial membrane sculpting protein with BAR domain-like activity
eLife 10:e60049.
https://doi.org/10.7554/eLife.60049

Share this article

https://doi.org/10.7554/eLife.60049

Further reading

    1. Immunology and Inflammation
    2. Microbiology and Infectious Disease
    Malika Hale, Kennidy K Takehara ... Marion Pepper
    Research Article

    Pseudomonas aeruginosa (PA) is an opportunistic, frequently multidrug-resistant pathogen that can cause severe infections in hospitalized patients. Antibodies against the PA virulence factor, PcrV, protect from death and disease in a variety of animal models. However, clinical trials of PcrV-binding antibody-based products have thus far failed to demonstrate benefit. Prior candidates were derivations of antibodies identified using protein-immunized animal systems and required extensive engineering to optimize binding and/or reduce immunogenicity. Of note, PA infections are common in people with cystic fibrosis (pwCF), who are generally believed to mount normal adaptive immune responses. Here, we utilized a tetramer reagent to detect and isolate PcrV-specific B cells in pwCF and, via single-cell sorting and paired-chain sequencing, identified the B cell receptor (BCR) variable region sequences that confer PcrV-specificity. We derived multiple high affinity anti-PcrV monoclonal antibodies (mAbs) from PcrV-specific B cells across three donors, including mAbs that exhibit potent anti-PA activity in a murine pneumonia model. This robust strategy for mAb discovery expands what is known about PA-specific B cells in pwCF and yields novel mAbs with potential for future clinical use.

    1. Microbiology and Infectious Disease
    Ziyu Wen, Pingchao Li ... Caijun Sun
    Research Article

    The persistence of latent viral reservoirs remains the major obstacle to eradicating human immunodeficiency virus (HIV). We herein found that ICP34.5 can act as an antagonistic factor for the reactivation of HIV latency by herpes simplex virus type I (HSV-1), and thus recombinant HSV-1 with ICP34.5 deletion could more effectively reactivate HIV latency than its wild-type counterpart. Mechanistically, HSV-ΔICP34.5 promoted the phosphorylation of HSF1 by decreasing the recruitment of protein phosphatase 1 (PP1α), thus effectively binding to the HIV LTR to reactivate the latent reservoirs. In addition, HSV-ΔICP34.5 enhanced the phosphorylation of IKKα/β through the degradation of IκBα, leading to p65 accumulation in the nucleus to elicit NF-κB pathway-dependent reactivation of HIV latency. Then, we constructed the recombinant HSV-ΔICP34.5 expressing simian immunodeficiency virus (SIV) env, gag, or the fusion antigen sPD1-SIVgag as a therapeutic vaccine, aiming to achieve a functional cure by simultaneously reactivating viral latency and eliciting antigen-specific immune responses. Results showed that these constructs effectively elicited SIV-specific immune responses, reactivated SIV latency, and delayed viral rebound after the interruption of antiretroviral therapy (ART) in chronically SIV-infected rhesus macaques. Collectively, these findings provide insights into the rational design of HSV-vectored therapeutic strategies for pursuing an HIV functional cure.